Orange Biomed Showcases Advanced Microfluidic A1c Test at MEDICA 2025

The system is designed for point of care and potential at home use, providing rapid A1C assessment in a compact form factor suited to clinical and near patient workflows.

OBM rapid A1c uses capillary‑scale microfluidic channels to physically assess red blood cell stiffness, marking a departure from conventional methods. The approach is intended to yield consistent readings regardless of hemoglobin variants, addressing a known source of variability in A1C testing among certain ethnic groups. The company is preparing a 510(k) submission to the U.S. Food and Drug Administration (FDA) for potential over-the-counter (OTC) clearance of the OBM rapid A1c device, with the goal of expanding access to innovative diabetes care solutions and enhancing patients’ quality of life.

“Orange Biomed is thrilled to return to MEDICA this year, an event that consistently takes place during Diabetes Awareness Month,” said Yeaseul Park, Co‑Founder and CEO of Orange Biomed “Following our proud recognition as one of Fortune Korea's ‘Top 40 Emerging South Korean Healthcare Innovations’ and the resounding success of our global ‘M.A.P. Your Health’ campaign, our commitment to patient‑centric diabetes care is stronger than ever. This event offers a unique opportunity to demonstrate how our novel approach to A1C testing can potentially transform diabetes monitoring, making it truly inclusive and accessible for people of all backgrounds.”

Related Links:
Orange Biomed